Top Markets
Coin of the day
Taisho Pharmaceutical Holdings Co., Ltd. Taisho Pharmaceutical Holdings Co., Ltd.

Taisho Pharmaceutical Holdings Co., Ltd.

4581
Classement en actions #3839
Taisho Pharmaceutical Holdings Co., Ltd. is a global healthcare enterprise... Taisho Pharmaceutical Holdings Co., Ltd. is a global healthcare enterprise involved in the comprehensive research, development, production, marketing, and distribution of both non-prescription (OTC) and ethical pharmaceutical products, serving markets in Japan and worldwide. The company's operations are divided into two principal divisions: the Self-Medication Operation Group and the Prescription Pharmaceutical Operation Group. The Self-Medication Group provides a diverse portfolio of consumer health products, including over-the-counter medicines, quasi-pharmaceuticals, food products, and general medical and hygiene items. Prominent brands within this segment include the Lipovitan energy drink series, Pabron cold and sinus remedies, RiUP hair re-growth solutions, Taisho Kampo gastrointestinal treatments, Colac laxatives, Naron and other pain relievers for fever, Preser hemorrhoid treatments, Hapacol, Efferalgan, Dafalgan, and Tempra for antipyretic-analgesic relief, Counterpain topical anti-inflammatory products, Vitacilina dermatological treatments, and VICKS cough suppressant throat lozenges and medicated drops. This division also encompasses real estate leasing, facility management, and hotel operations. Conversely, the Prescription Pharmaceutical Group specializes in ethical drugs such as Edirol, an active vitamin D3 agent for osteoporosis; Clarith, a macrolide antibiotic; Palux, a peripheral vasodilator; Bonviva, a bisphosphonate for osteoporosis; Lusefi, an agent for type 2 diabetes mellitus; and LOQOA, a transdermal anti-inflammatory analgesic. This segment is also engaged in ongoing drug development, primarily focusing on therapeutic areas like central nervous system disorders, infectious diseases, metabolic conditions, and orthopedic ailments. Additionally, Taisho Pharmaceutical Holdings supplies raw materials for pharmaceutical and quasi-drug manufacturing, alongside offering health foods and skincare products. The company was established in Tokyo, Japan, in 1912, where its headquarters remain.
Prix de l'action
$55.98
Dernière synchronisation: 2024-04-08
Capitalisation boursière
$4.59B
Changement (1 jour)
-1.20%
Changement (1 an)
0.00%
Pays
JP
Échange Taisho Pharmaceutical Holdings Co., Ltd. (4581)

Catégorie

Le prix 4581 avec la capitalisation boursière de B
Taisho Pharmaceutical Holdings Co., Ltd. Taisho Pharmaceutical Holdings Co., Ltd.
4581
$55.98
Capitalisation boursière de Taisho Pharmaceutical Holdings Co., Ltd.(4581)
Capitalisation boursière: $4.59B
En August 2026, Taisho Pharmaceutical Holdings Co., Ltd. a une capitalisation boursière de $4.59B. Cela fait de Taisho Pharmaceutical Holdings Co., Ltd. la 3839th entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de Taisho Pharmaceutical Holdings Co., Ltd. du 2011 au 2026
4581 par rapport au top 5 des plus populaires stocks
Prix pour 4581 L’actif B La capitalisation boursière de B Résultats
Taisho Pharmaceutical Holdings Co., Ltd. Taisho Pharmaceutical Holdings Co., Ltd.
$62,860.00 $4.59B
$5.152T +112,191.92%
Taisho Pharmaceutical Holdings Co., Ltd. Taisho Pharmaceutical Holdings Co., Ltd.
$55,351.35 $4.59B
$4.537T +98,778.61%
Taisho Pharmaceutical Holdings Co., Ltd. Taisho Pharmaceutical Holdings Co., Ltd.
$50,856.25 $4.59B
$4.169T +90,748.65%
Taisho Pharmaceutical Holdings Co., Ltd. Taisho Pharmaceutical Holdings Co., Ltd.
$44,436.43 $4.59B
$3.642T +79,280.41%
Taisho Pharmaceutical Holdings Co., Ltd. Taisho Pharmaceutical Holdings Co., Ltd.
$34,217.20 $4.59B
$2.805T +61,024.96%